Food and Drug Administration Information Technology Strategy; Request for Comments; Correction, 69932 [2023-22388]
Download as PDF
<![CDATA[
69932
Federal Register / Vol. 88, No. 194 / Tuesday, October 10, 2023 / Notices
the terms of the generic. Burden
estimates have been updated.
DATES: Comments due within 30 days of
publication. OMB must make a decision
about the collection of information
between 30 and 60 days after
publication of this document in the
Federal Register. Therefore, a comment
is best assured of having its full effect
if OMB receives it within 30 days of
publication.
Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review-Open
for Public Comments’’ or by using the
search function. You can also obtain
copies of the proposed collection of
information by emailing
ADDRESSES:
collection activity under this generic
clearance. Each request will include the
individual form(s) or instrument(s), a
justification specific to the individual
information collection, and any
supplementary documents. OMB is
requested to review requests within 10
days of submission.
Respondents: ACF funding recipients.
Annual Burden Estimates
This request will extend approval of
currently approved monitoring forms.
Currently approved forms and related
burden can be found here: https://
www.reginfo.gov/public/do/
PRAICList?ref_nbr=202307-0970-014.
Burden estimates for the next three
years have been updated to reflect
trends in use over the past three years.
These are based on averages and actual
individual requests will vary based on
program office need.
Instrument
Number of
respondents
(total over
request
period)
Number of
responses per
respondent
(total over
request
period)
Avg. burden
per response
(in hours)
Total burden
(in hours)
New Program Monitoring Forms ....................................................................
1600
2.5
12
48,000
Mary B. Jones,
ACF/OPRE Certifying Officer.
year information. This document
corrects that error.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2023–22382 Filed 10–6–23; 8:45 am]
FOR FURTHER INFORMATION CONTACT:
Casi
Alexander, Office of Digital
Transformation, Food and Drug
Administration, FDA Library, 5630
Fishers Lane, Rm. 1087, Rockville, MD
20857, 240–402–5171, email:
Casi.Alexander@fda.hhs.gov.
Food and Drug Administration
In the
Federal Register of September 19, 2023
(88 FR 64435), in FR Doc. 2023–20136,
the following correction is made:
On page 64436, in the third column,
in the second paragraph, ‘‘Fiscal Years
2024–2026’’ is corrected to read ‘‘Fiscal
Years 2024–2027.’’
AGENCY:
BILLING CODE 4184–79–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
SUPPLEMENTARY INFORMATION:
[Docket No. FDA–2023–N–3636]
Food and Drug Administration
Information Technology Strategy;
Request for Comments; Correction
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice; correction.
The Food and Drug
Administration (FDA or Agency) is
correcting a notice entitled ‘‘Food and
Drug Administration Information
Technology Strategy; Request for
Comments’’ that appeared in the
Federal Register of September 19, 2023.
The document announced the
availability of an information
technology (IT) strategic plan entitled
the ‘‘FDA Information Technology
Strategy’’ and a request for comment on
this IT Strategy. The document was
published with an incorrect set of fiscal
SUMMARY:
ddrumheller on DSK120RN23PROD with NOTICES1
OPREinfocollection@acf.hhs.gov.
Identify all requests by the title of the
information collection.
SUPPLEMENTARY INFORMATION:
Description: Program monitoring is a
post-award process through which ACF
assesses a recipient’s programmatic
performance and business management
performance. Monitoring activities are
necessary to ensure timely action by
ACF to support grantees and protect
federal interests.
Program offices use information
collected under this generic clearance to
monitor funding recipient activities and
to provide support or take appropriate
action, as needed. The information
gathered is or will be used primarily for
internal purposes, but aggregate data
may be included in public materials
such as Reports to Congress or program
office documents. Following standard
OMB requirements, ACF will submit a
request for each individual data
VerDate Sep<11>2014
18:39 Oct 06, 2023
Jkt 262001
Dated: October 4, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023–22388 Filed 10–6–23; 8:45 am]
BILLING CODE 4164–01–P
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
[Docket No. FDA–2023–N–4202]
Revocation of Two Authorizations of
Emergency Use of In Vitro Diagnostic
Devices for Detection and/or Diagnosis
of Mpox; Availability
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing the
revocations of the Emergency Use
Authorizations (EUAs) (the
Authorizations) issued to Life
Technologies Corp. (a part of Thermo
Fisher Scientific Inc.), for the TaqPath
Monkeypox/Orthopox Virus DNA Kit,
and Becton, Dickinson and Co., for the
VIASURE Monkeypox virus Real Time
PCR Reagents for BD MAX System. FDA
revoked these Authorizations under the
Federal Food, Drug, and Cosmetic Act
(FD&C Act) as requested by these
Authorization holders. The revocations,
which include an explanation of the
reasons for each revocation, are
reprinted in this document.
DATES: The Authorization for the Life
Technologies Corp. (a part of Thermo
SUMMARY:
E:\FR\FM\10OCN1.SGM
10OCN1
]]>Agencies
[Federal Register Volume 88, Number 194 (Tuesday, October 10, 2023)]
[Notices]
[Page 69932]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-22388]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2023-N-3636]
Food and Drug Administration Information Technology Strategy;
Request for Comments; Correction
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; correction.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) is correcting
a notice entitled ``Food and Drug Administration Information Technology
Strategy; Request for Comments'' that appeared in the Federal Register
of September 19, 2023. The document announced the availability of an
information technology (IT) strategic plan entitled the ``FDA
Information Technology Strategy'' and a request for comment on this IT
Strategy. The document was published with an incorrect set of fiscal
year information. This document corrects that error.
FOR FURTHER INFORMATION CONTACT: Casi Alexander, Office of Digital
Transformation, Food and Drug Administration, FDA Library, 5630 Fishers
Lane, Rm. 1087, Rockville, MD 20857, 240-402-5171, email:
[email protected].
SUPPLEMENTARY INFORMATION: In the Federal Register of September 19,
2023 (88 FR 64435), in FR Doc. 2023-20136, the following correction is
made:
On page 64436, in the third column, in the second paragraph,
``Fiscal Years 2024-2026'' is corrected to read ``Fiscal Years 2024-
2027.''
Dated: October 4, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023-22388 Filed 10-6-23; 8:45 am]
BILLING CODE 4164-01-P
